We are live on ! Find out more
QUSVM

Qiming U.S. Ventures Management Portfolio holdings

AUM $55.6M
1-Year Est. Return 98.09%
This Fund
S&P 500
This Quarter Est. Return
+116.23%
1 Year Est. Return
+98.09%
3 Year Est. Return
+1,484.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$89.7M
AUM Growth
-$19.5M
Cap. Flow
-$53M
Cap. Flow %
-59.04%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
2
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$3.53M
2
JSPR icon
Jasper Therapeutics
JSPR
+$1.37M

Top Sells

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$55.3M
2
ELEV
Elevation Oncology
ELEV
+$1.27M
3
VTYX
Ventyx Biosciences
VTYX
+$1.25M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRRO icon
1
Korro Bio
KRRO
$195M
$33.1M 36.93%
368,085
– –
JSPR icon
2
Jasper Therapeutics
JSPR
$23.3M
$27.3M 30.41%
928,964
+76,999
+9% +$1.37M
TRML
3
DELISTED
Tourmaline Bio
TRML
$17M 18.94%
741,691
+100,000
+16% +$3.53M
HLVX
4
DELISTED
HilleVax
HLVX
$9.29M 10.36%
558,923
– –
VTYX
5
DELISTED
Ventyx Biosciences
VTYX
$2.27M 2.53%
412,225
-274,145
-40% -$1.25M
KZR
6
DELISTED
Kezar Life Sciences
KZR
$747K 0.83%
82,871
– –
ELEV
7
DELISTED
Elevation Oncology
ELEV
– –
-2,370,142
Closed -$1.27M
ICVX
8
DELISTED
Icosavax, Inc. Common Stock
ICVX
– –
-3,510,228
Closed -$55.3M

Similar funds

CCCPV
Castle Creek Capital Partners VI San Diego, California $55.9M AUM 7.91% 1-Year Est. Return
ACM
Aurelius Capital Management New York $55.2M AUM 124.79% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
NCFG
New Century Financial Group Princeton, New Jersey $56.3M AUM 16.99% 1-Year Est. Return
LAM
Lingohr Asset Management Duesseldorf, Germany $57.3M AUM 35.27% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
ITVII
IDG Technology Venture Investment IV Hong Kong $58.3M AUM 89.42% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Qiming U.S. Ventures Management's Q1 2024 Portfolio in Review

As of Q1 2024, Qiming U.S. Ventures Management held 8 positions worth $89.7M, down 18% from $109M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Qiming U.S. Ventures Management withdrew a net $53M in Q1 2024, closing 2 positions and reducing 1 holding. Its most notable exit was Icosavax, Inc. Common Stock, an estimated $55.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Qiming U.S. Ventures Management added an estimated $3.53M to Tourmaline Bio.

  • Qiming U.S. Ventures Management added most to Tourmaline Bio in Q1 2024, an estimated $3.53M increase.
  • Qiming U.S. Ventures Management's biggest Q1 2024 reduction was Ventyx Biosciences, cutting an estimated $1.25M.
  • Qiming U.S. Ventures Management fully exited Icosavax, Inc. Common Stock in Q1 2024, selling an estimated $55.3M.
  • Qiming U.S. Ventures Management's ten largest holdings make up 100% of its $89.7M portfolio in Q1 2024.
  • Qiming U.S. Ventures Management opened 0 new positions and closed 2 in Q1 2024.
  • Qiming U.S. Ventures Management's portfolio value fell 18% quarter-over-quarter to $89.7M.

Based on Qiming U.S. Ventures Management's 13F filing for Q1 2024, filed 14 May 2024.